My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: usually no — compounded GLP‑1s are rarely the best first option. They can be cheaper or easier to get, but they carry real safety, quality and legal risks and lack the FDA-approved manufacturing and testing that Wegovy (semaglutide 2.4 mg) has. There are safer, often better paths to pursue first.

What to consider and practical next steps

1. Appeal the denial first

• Ask your prescriber to submit a formal prior‑authorization appeal or peer‑to‑peer review with the insurer and to write a letter of medical necessity documenting your BMI, weight‑related conditions, prior therapies tried, and why Wegovy is clinically indicated. Denials are often reversed on appeal.
• If you want, I can help draft a short appeal/medical‑necessity paragraph you can give your clinician.

1. Check manufacturer and savings programs

• Novo Nordisk offers patient support and savings programs for Wegovy. If you have commercial insurance, co‑pay savings or patient support may reduce cost; for Medicare recipients, manufacturer coupons usually aren’t allowed, but patient assistance programs may still help. Contact Novo Nordisk Patient Support for details.

1. Consider alternative, FDA‑approved options (safer than compounding)

• Zepbound (tirzepatide, Eli Lilly) — FDA‑approved for chronic weight management; may be covered differently by insurers and is very effective for weight loss.
• Mounjaro (tirzepatide, Lilly) — approved for type 2 diabetes but commonly used off‑label for weight loss; discuss this with your clinician.
• Ozempic (semaglutide, Novo Nordisk) — approved for diabetes; some clinicians use it off‑label at higher doses for weight management.
• Saxenda (liraglutide, Novo Nordisk) — older daily injectable weight‑loss drug, FDA‑approved for obesity. These have established safety data and manufacturer quality controls; your prescriber can try switching or request coverage for one of these.

1. Clinical trials and programs

• Look for clinical trials of GLP‑1 or tirzepatide products (ClinicalTrials.gov) — some trials provide medication at no cost.

1. If you’re thinking about compounded GLP‑1s — major cautions

• Compounded GLP‑1s are not FDA‑approved products. Quality (potency, purity) and sterility can vary. There have been reports of contamination, incorrect dosing, and supply of unauthorized ingredients.
• Insurance typically won’t cover compounded versions.
• If you still consider compounding, only use a reputable, accredited compounding pharmacy (look for PCAB accreditation and documented sterility/potency testing). Ask the pharmacy for their certificate of analysis, sterility testing procedures, lot records, and how the active pharmaceutical ingredient is sourced.
• Be extremely cautious about mail‑order or overseas sources, and avoid “too good to be true” prices.

1. Other options to discuss with your clinician

• Intensified lifestyle program, referral to a registered dietitian or behavioral program.
• Bariatric surgery evaluation if you meet criteria.
• Older, non-GLP‑1 medicines for weight management (Contrave, Qsymia) if appropriate.

Summary recommendation

• Don’t jump to compounded GLP‑1s as the first fix. First: appeal the denial, check Novo Nordisk’s support programs, and ask your clinician about covered FDA‑approved alternatives such as Zepbound, Mounjaro, Ozempic, or Saxenda. Reserve compounding only as a last‑resort after careful vetting of a PCAB‑accredited pharmacy and full informed discussion about risks.

If you want, tell me:

• Your insurance type (commercial, Medicare, Medicaid), BMI and any weight‑related conditions, and whether your clinician has tried an appeal — and I can help draft an appeal letter or suggest the most promising alternative based on your situation.